Anti-NY-ESO-1 Antibody, clone D8.38

Evaluated by Immunohistochemistry in human testis tissue.

Immunohistochemistry Analysis: A 1:250 dilution of this antibody detected NY-ESO-1 in human testis tissue.

Detect NY-ESO-1, LAGE-1 using this mouse monoclonal Anti-NY-ESO-1 antibody, clone D8.38, Cat. No. MABC1151. Validated for use in Immunohistochemistry (Paraffin).

Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected NY-ESO-1 in human testis tissue.

Immunohistochemistry Analysis: A representative lot detected NY-ESO-1 in Immunohistochemistry applications. (Yakirevich, E., et. al. (2003). Clin Cancer Res. 9(17):6453-60; Bujas, T., et. al. (2011). Eur J Histochem. 55(1):e7; Bolli, M., et. al. (2005). Int J Cancer. 115(6):960-6; Groeper, C., et. al. (2007). Int J Cancer. 120(2):337-43).

Research Category
Apoptosis & Cancer

Clone D8.38 specifically targets a sequence in the N-terminal region and detects Cancer/testis antigen 1 (NY-ESO1) in human testis

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

17.99 kDa calculated.

Cancer/testis antigen 1 (UniProt: P78358; also known as Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CT6.1, L antigen family member 2, LAGE-2) is encoded by the CTAG1A (also known as CTAG, CTAG1, ESO1, LAGE2, LAGE2A, CTAG1B, LAGE2B) gene (Gene ID: 1485; 246100) in human. NY-ESO-1 is a human tumor antigen of the cancer/testis family that is highly expressed in many poor-prognosis melanomas and in other cancer types. However, it is not detected in non-malignant tissues with the exception of germ cells and trophoblasts. It contains a C-terminal hydrophobic tail that potentially serves as membrane-associated domain. NY-ESO-1 is expressed from 18 weeks until birth in human fetal testis and in adult testis it is strongly expressed in spermatogonia and in primary spermatocytes, but not in post-meiotic cells or in testicular somatic cells. Although the exact function of NY-ESO-1 is still not clear, it has been speculated it might contribute to certain properties, such as immortality, self-renewal, migratory ability, and capacity to invade that favor tumor cell survival. On the basis of its immunogenicity, NY-ESO-1 is considered as one of the most attractive antigens for cancer immunotherapy. T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1 have been considered as an attractive method for treatment of myeloma and enhance long-term survival of cells.

A full length recombinant human NY-ESO-1 protein.

Epitope: domain of:

Concentration: Please refer to lot specific datasheet.

Format: Purified

Protein G purified

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.